Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling

1 Dec 2009

Abstract excerpt

BACKGROUND: 5-Fluorouracil(5FU) and oral analogues, such as capecitabine, remain one of the most useful agents for the treatment of colorectal adenocarcinoma. Low toxicity and convenience of administration facilitate use, however clinical resistance is a major limitation. Investigation has failed to fully explain the molecular mechanisms of resistance and no clinically useful predictive biomarkers for 5FU...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Cancer Surgical Treatments
Share to Colorectal Cancer Treatments and Studies
Share to Genetic factors in colorectal cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20003335
DOI: 10.1186/1471-2407-9-434

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profilingPMID 20003335Read ↗

Cancer-associated fibroblast signature and SMAD4 mutation in resistance to adjuvant chemotherapy in stage III colon cancer patients.Semantic proximity Read ↗

Chemoresponsiveness associated with canonical molecular changes in colorectal adenocarcinomas.Semantic proximity Read ↗

Molecular determinants of efficacy for 5‐FU‐based treatments in advanced colorectal cancer: mRNA expression for 18 chemotherapy‐related genesSemantic proximity Read ↗

Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancerSemantic proximity Read ↗

Oxaliplatin induces different cellular and molecular chemoresistance patterns in colorectal cancer cell lines of identical origins.Semantic proximity Read ↗

Downregulation of KRAB zinc finger proteins in 5-fluorouracil resistant colorectal cancer cellsSemantic proximity Read ↗

Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cellsSemantic proximity Read ↗

Comparison of gene expression in HCT116 treatment derivatives generated by two different 5-fluorouracil exposure protocols.Semantic proximity Read ↗

Deciphering cellular states of innate tumor drug responsesSemantic proximity Read ↗

A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer.Semantic proximity Read ↗

Autocrine induction of invasive and metastatic phenotypes by the MIF-CXCR4 axis in drug-resistant human colon cancer cells.Semantic proximity Read ↗

Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.